CA3263920A1 - MULTI-SPECIFIC POLYPEPTIDE COMPLEXES - Google Patents

MULTI-SPECIFIC POLYPEPTIDE COMPLEXES

Info

Publication number
CA3263920A1
CA3263920A1 CA3263920A CA3263920A CA3263920A1 CA 3263920 A1 CA3263920 A1 CA 3263920A1 CA 3263920 A CA3263920 A CA 3263920A CA 3263920 A CA3263920 A CA 3263920A CA 3263920 A1 CA3263920 A1 CA 3263920A1
Authority
CA
Canada
Prior art keywords
specific polypeptide
polypeptide complexes
complexes
specific
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3263920A
Other languages
English (en)
French (fr)
Inventor
Zhenhao Zhou
Jie Zhang
Gong Wang
Original Assignee
Shanghai Kaijin Biotechnology Ltd
Chimagen Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kaijin Biotechnology Ltd, Chimagen Biosciences Ltd filed Critical Shanghai Kaijin Biotechnology Ltd
Publication of CA3263920A1 publication Critical patent/CA3263920A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3263920A 2022-08-05 2023-02-07 MULTI-SPECIFIC POLYPEPTIDE COMPLEXES Pending CA3263920A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/110697 2022-08-05
CN2022110697 2022-08-05
PCT/CN2023/074836 WO2024027120A1 (en) 2022-08-05 2023-02-07 Multi-specific polypeptide complexes

Publications (1)

Publication Number Publication Date
CA3263920A1 true CA3263920A1 (en) 2024-02-08

Family

ID=89848477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3263920A Pending CA3263920A1 (en) 2022-08-05 2023-02-07 MULTI-SPECIFIC POLYPEPTIDE COMPLEXES

Country Status (6)

Country Link
EP (1) EP4565620A1 (https=)
JP (1) JP2025528101A (https=)
CN (1) CN119998329A (https=)
AU (1) AU2023318846A1 (https=)
CA (1) CA3263920A1 (https=)
WO (1) WO2024027120A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177643B1 (en) * 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CR20210330A (es) * 2018-12-21 2021-07-20 Hoffmann La Roche ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
CA3124688A1 (en) * 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
WO2020156405A1 (en) * 2019-01-28 2020-08-06 Wuxi Biologics (Shanghai) Co. Ltd. Novel bispecific cd3/cd20 polypeptide complexes
IL302412A (en) * 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
AU2023318846A1 (en) 2025-02-27
CN119998329A (zh) 2025-05-13
JP2025528101A (ja) 2025-08-26
WO2024027120A1 (en) 2024-02-08
EP4565620A1 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
CA3243249A1 (en) NEW PEPTIDES
EP4172173A4 (en) NEUTROPHIL-BINDING PEPTIDES
CA3279153A1 (en) Multi-specific polypeptide complexes
CA3263920A1 (en) MULTI-SPECIFIC POLYPEPTIDE COMPLEXES
AU2023403090A1 (en) Recombinant polypeptide
AU2024205312A1 (en) Binarual rendering
EP4223878A4 (en) SARS-COV-2 BINDING PEPTIDE
CA3278078A1 (en) Multi-specific polypeptide complex targeting gprc5d
AU2024265436A1 (en) New polypeptide
CA3290202A1 (en) New polypeptide
CA3287591A1 (en) Recombinant phytoglobins
AU2023901720A0 (en) Autophagy-inducing peptides
HK40104862A (en) Heterotandem bicyclic peptide complexes
HK40114804A (zh) 新型多肽
HK40121780A (en) Novel polypeptides
HK40121779A (en) Novel polypeptides
CA3274058A1 (en) Recombinant polypeptide
CA3291205A1 (en) Complex
AU2022903684A0 (en) Recombinant Polypeptide
AU2025902942A0 (en) Variant polypeptides
HK40113842A (zh) 多肽
AU2024363125A1 (en) Stabilized polypeptides
CA3308182A1 (en) Stabilized polypeptides
HK40111298A (en) Novel peptides
AU2023901759A0 (en) Not Alone

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250507

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260113